Arrowhead Pharmaceuticals (ARWR) 424B7 Prospectus with selling stockholder info

0000879407424B7EX-FILING FEESCommon stock, par value $0.001 per share 0000879407 2025-03-06 2025-03-06 0000879407 1 2025-03-06 2025-03-06 iso4217:USD xbrli:pure xbrli:shares

Exhibit 107

Calculation of Filing Fee Tables

FORM

424(b)(7)

(Form Type)

Arrowhead Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

Security Type

Security Class Title

Fee  Calculation  or Carry Forward Rule

Amount Registered

Proposed Maximum Offering Price Per Unit

Maximum Aggregate Offering Price

Fee Rate

Amount of Registration Fee

Carry Forward Form Type

Carry Forward File Number

Carry Forward  Initial effective date

Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward

Newly Registered Securities

Fees to Be Paid

Equity

Common stock, par value $0.001 per share(1)

Rule 457(r)

11,926,301

$17.03

$203,104,906.03(2)

0.0001531

$ 31,095.36

Carry Forward Securities

Carry Forward Securities

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Total Offering Amounts

$203,104,906.03

$31,095.36

Total Fees Previously Paid

—

Total Fee Offsets

—

Net Fee Due

$31,095.36

(1) Pursuant to Rule 416 under the Securities Act, this prospectus supplement also covers such an indeterminate amount of shares of common stock as may become issuable to prevent dilution resulting from stock splits, stock dividends and similar events.

(2) Estimated solely for the purpose of calculating the registration fee, based on the average of the high and low prices of the shares of common stock on The Nasdaq Global Select Market on March 4, 2025 (such date being within five business days of the date that this registration statement was first filed with the Securities and Exchange Commission, in accordance with Rule 457(c) under the Securities Act). Represents deferred payment of the registration fees in connection with the Registrant’s registration statement on Form S-3ASR (Registration No. 333-268665) paid with the filing of this prospectus supplement.